# John M. Lachin

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/john-m-lachin/

## Facts

| Field | Value |
| --- | --- |
| Citations | 55,595 |
| Field | Diabetes Management and Research |
| h-index | 100 |
| i10-index | 288 |
| Last Known Institution | Christian Doppler Laboratory for Thermoelectricity |
| OpenAlex ID | https://openalex.org/A5035897807 |
| ORCID iD | 0000-0001-9838-2841 |
| Works | 526 |

## Researcher papers

Showing 12 of 18.

- [Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes](https://scholariq.org/papers/empagliflozin-cardiovascular-outcomes-and-mortality-in-type-2-diabetes/)
- [Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes](https://scholariq.org/papers/empagliflozin-and-progression-of-kidney-disease-in-type-2-diabetes/)
- [Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy](https://scholariq.org/papers/glycemic-durability-of-rosiglitazone-metformin-or-glyburide-monotherapy/)
- [Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes](https://scholariq.org/papers/effect-of-sitagliptin-on-cardiovascular-outcomes-in-type-2-diabetes/)
- [Effect of Weight Loss With Lifestyle Intervention on Risk of Diabetes](https://scholariq.org/papers/effect-of-weight-loss-with-lifestyle-intervention-on-risk-of-diabetes/)
- [Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function](https://scholariq.org/papers/rituximab-b-lymphocyte-depletion-and-preservation-of-beta-cell-function/)
- [Introduction to sample size determination and power analysis for clinical trials](https://scholariq.org/papers/introduction-to-sample-size-determination-and-power-analysis-for-clinical-trials/)
- [Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME <sup>®</sup> trial](https://scholariq.org/papers/heart-failure-outcomes-with-empagliflozin-in-patients-with-type-2-diabetes-at/)
- [How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial](https://scholariq.org/papers/how-does-empagliflozin-reduce-cardiovascular-mortality-insights-from-a-mediation/)
- [Statistical Considerations in the Intent-to-Treat Principle](https://scholariq.org/papers/statistical-considerations-in-the-intent-to-treat-principle/)
- [C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve β-Cell Function](https://scholariq.org/papers/c-peptide-is-the-appropriate-outcome-measure-for-type-1-diabetes-clinical-trials/)
- [Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease](https://scholariq.org/papers/empagliflozin-and-clinical-outcomes-in-patients-with-type-2-diabetes-mellitus/)

## Researcher topics

- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Statistical Methods in Clinical Trials](https://scholariq.org/topics/statistical-methods-in-clinical-trials/)
- [Diabetes and associated disorders](https://scholariq.org/topics/diabetes-and-associated-disorders/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)

## Researcher university

- [Christian Doppler Laboratory for Thermoelectricity](https://scholariq.org/institutions/christian-doppler-laboratory-for-thermoelectricity/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.